Opportunity Information: Apply for RFA OD 10 010
Apply for RFA OD 10 010
- The National Institutes of Health in the health recovery act sector is offering a public funding opportunity titled "Recovery Act Limited Competition Research On Biosamples From Selected Diabetes Clinical Studies (RC4)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.701 Trans NIH Recovery Act Research Support.
- This funding opportunity was created on Jan 4, 2010 and posted on Jan 4, 2010.
- Applicants must submit their applications by Mar 11, 2010. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $3,000,000.00 to eligible and selected applicants.
- Eligible applicants include: Private institutions of higher education City or township governments Special district governments Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities For profit organizations other than small businesses County governments Small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Others (see text field entitled Additional Information on Eligibility for clarification) Native American tribal organizations (other than Federally recognized tribal governments) State governments Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Recovery Act Limited Competition Research On Biosamples From Selected Diabetes Clinical Studies (RC4) funding opportunity (RFA-OD-10-010) was an NIH grant program financed through the American Recovery and Reinvestment Act of 2009 (ARRA). Its main goal was to quickly accelerate high-value diabetes research by letting investigators use existing, scarce human biospecimens that had already been collected during specific NIDDK-supported diabetes clinical trials and studies, rather than spending time and money launching new sample collections. The emphasis was on extracting additional scientific insight from these well-characterized clinical cohorts while staying aligned with the original studies and the participant consent terms.
The program supported two closely related application paths. First, applicants could request access to limited, nonrenewable biosamples (explicitly excluding DNA) from selected NIDDK-funded diabetes clinical studies and also request funding to run validated laboratory assays on those samples. Second, applicants who already had (or could document) approved access to the same types of samples through the relevant study consortia could apply for funding strictly for the assay work, with proof that access had been authorized. In both cases, the biospecimens had to come from the specific studies covered by the announcement, and the proposed work needed to test scientifically strong hypotheses that fit the original goals of the parent trial or study.
A key boundary of the opportunity was that it was not meant for early-stage method building. The FOA did not provide support for developing new assays, for exploratory animal model research, or for any projects using samples outside the listed NIDDK diabetes trials and studies. The intent was to fund work that could move quickly because the assays were already validated and the samples were already available, with the Recovery Act focus on rapid, tangible research output.
Another major expectation was data sharing back to the originating research community. Any data generated under this award was expected to be returned to the relevant consortium or to an NIDDK repository, helping ensure that results would strengthen the value of these finite biospecimens for the broader diabetes research field and extend the usefulness of the original clinical studies.
In terms of award structure, NIH used the RC4 grant mechanism for this competition. NIDDK planned to commit up to $3,000,000 total, with an anticipated 5 to 10 awards in fiscal year 2010 depending on application volume, scientific quality, and funds availability. The opportunity was categorized as discretionary grant funding in the health area and was tied to the NIH Recovery Act Research Support CFDA listing (93.701).
Eligibility was broad and included many types of organizations and governments. Eligible applicants included public and private institutions of higher education, nonprofit organizations (both with and without 501(c)(3) status), for-profit organizations (including small businesses and other for-profits), and a range of government entities (state, county, city/township, special district, and certain housing authorities). It also included tribal governments and tribal organizations, U.S. territories or possessions, regional organizations, and a variety of designated institution types such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, and Alaska Native and Native Hawaiian serving institutions, along with faith-based and community-based organizations and eligible federal agencies.
Administratively, the FOA was posted January 4, 2010, with an application closing date of March 11, 2010, and it was later archived April 11, 2010. The sponsoring agency was the National Institutes of Health, and the full announcement was made available through the NIH grants site under the RFA link provided in the source text.
Frequently Asked Questions (FAQs)
What is the Recovery Act Limited Competition Research On Biosamples From Selected Diabetes Clinical Studies (RC4) opportunity?
This was an NIH funding opportunity (RFA-OD-10-010) supported by the American Recovery and Reinvestment Act of 2009 (ARRA). It was designed to rapidly accelerate high-value diabetes research by enabling investigators to use existing, scarce human biospecimens from specific NIDDK-supported diabetes clinical trials and studies, rather than starting new sample collection efforts.
What was the main purpose of this funding opportunity?
The main purpose was to generate additional scientific insight quickly from well-characterized diabetes clinical cohorts by using already-collected, limited human biospecimens and running validated laboratory assays to test strong, hypothesis-driven research questions aligned with the original parent trials or studies and participant consent terms.
Which agency sponsored this opportunity?
The sponsoring agency was the National Institutes of Health (NIH).
Which NIH institute's studies and biosamples were the focus?
The opportunity focused on biospecimens collected during selected diabetes clinical trials and studies supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
What kind of research did the program prioritize?
The program prioritized research that could move quickly because it relied on existing biosamples and already validated laboratory assays, with the goal of producing rapid, tangible research output consistent with Recovery Act goals.
What types of biospecimens could be used under this FOA?
The FOA supported use of limited, nonrenewable human biosamples obtained from the specific NIDDK-funded diabetes clinical studies covered by the announcement.
Were DNA samples allowed under this funding opportunity?
No. The FOA explicitly excluded DNA from the biosamples that could be requested under the program.
Did the FOA allow projects using biospecimens from studies outside the listed NIDDK diabetes trials and studies?
No. Projects using samples outside the specific studies covered by the announcement were not supported under this opportunity.
What were the two application paths supported by this program?
The FOA supported two related paths: (1) applicants could request access to limited, nonrenewable biosamples (excluding DNA) from selected NIDDK-funded diabetes clinical studies and request funds to conduct validated laboratory assays on those samples; or (2) applicants who already had, or could document, approved access to the same types of samples through the relevant study consortia could apply for funding only for the assay work, with proof that access had been authorized.
If an applicant already had approved sample access, what could they request funding for?
They could apply for funding strictly for the validated laboratory assay work, provided they could document that biosample access had been approved through the relevant study consortia.
What scientific expectations were placed on proposed projects?
Proposed work needed to test scientifically strong hypotheses and remain aligned with the original goals of the parent diabetes trial or study, while also staying within participant consent terms.
Did this opportunity fund development of new assays?
No. The FOA was not meant for early-stage method building and did not support developing new assays. It focused on work using assays that were already validated.
Did this opportunity support exploratory animal model research?
No. The FOA did not provide support for exploratory animal model research.
What data sharing expectations applied to awardees?
Data generated under the award was expected to be returned to the relevant consortium or to an NIDDK repository. This was intended to strengthen the value of these finite biospecimens for the broader diabetes research community and extend the usefulness of the original clinical studies.
What grant mechanism was used for this competition?
NIH used the RC4 grant mechanism for this limited competition.
How much funding was planned for the program, and how many awards were anticipated?
NIDDK planned to commit up to $3,000,000 total, with an anticipated 5 to 10 awards in fiscal year 2010, depending on application volume, scientific quality, and availability of funds.
How was this opportunity categorized in terms of funding type and area?
It was categorized as discretionary grant funding in the health area and was tied to the NIH Recovery Act Research Support CFDA listing (93.701).
Who was eligible to apply?
Eligibility was broad. Eligible applicants included public and private institutions of higher education; nonprofit organizations (with or without 501(c)(3) status); for-profit organizations (including small businesses and other for-profits); and many government entities (state, county, city/township, special district, and certain housing authorities). Eligibility also included tribal governments and tribal organizations, U.S. territories or possessions, regional organizations, faith-based and community-based organizations, designated institution types (such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions), and eligible federal agencies.
Was this a limited competition opportunity?
Yes. It was a limited competition focused on accessing scarce, nonrenewable biosamples from selected NIDDK-supported diabetes clinical studies and performing validated assays on those materials.
When was the FOA posted, and what were the key dates?
The FOA was posted on January 4, 2010. The application closing date was March 11, 2010. The opportunity was later archived on April 11, 2010.
Is this funding opportunity still active?
No. Based on the provided information, the announcement was archived on April 11, 2010.
Where was the full announcement made available?
The full announcement was made available through the NIH grants site under the RFA link referenced in the source text.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Health Recovery Act
Next opportunity: NIH Support for Conferences and Scientific Meetings (Parent R13/U13)
Previous opportunity: Recovery Act BLM NV Black Rock Transportation Plan Project
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA OD 10 010
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA OD 10 010) also looked into and applied for these:
| Funding Opportunity |
|---|
| ARRA OS Recovery Act 2009 Accelerating Adoption of Comparative Effectiveness Research Results by Providers and Patients (R18) Apply for RFA AE 10 001 Funding Number: RFA AE 10 001 Agency: National Institutes of Health Category: Health Recovery Act Funding Amount: Case Dependent |
| Recovery Act Limited Competition Institutional Comparative Effectiveness Research Mentored Career Development Award (KM1) Apply for RFA OD 10 011 Funding Number: RFA OD 10 011 Agency: National Institutes of Health Category: Health Recovery Act Funding Amount: Case Dependent |
| ARRA OS Recovery Act 2009 Limited Competition Enhanced Registries for Quality Improvement and Comparative Effectiveness Research (R01) Apply for RFA HS 10 020 Funding Number: RFA HS 10 020 Agency: Agency for Health Care Research and Quality Category: Health Recovery Act Funding Amount: $4,000,000 |
| Recovery Act Limited Competition Framework Programs for Global Health Signature Innovations Initiative (R24) Apply for RFA OD 10 007 Funding Number: RFA OD 10 007 Agency: National Institutes of Health Category: Health Recovery Act Funding Amount: $250,000 |
| Recovery Act Limited Competition Program to Enhance NIH supported Global Health Research Involving Human Subjects (S07) Apply for RFA OD 10 006 Funding Number: RFA OD 10 006 Agency: National Institutes of Health Category: Health Recovery Act Funding Amount: $50,000 |
| ARRA OS Recovery Act 2009 Limited Competition Accelerating Implementation of Comparative Effectiveness Findings on Clinical and Delivery System Interventions by Leveraging AHRQ Networks (R18) Apply for RFA HS 10 014 Funding Number: RFA HS 10 014 Agency: Agency for Health Care Research and Quality Category: Health Recovery Act Funding Amount: $16,660,000 |
| ARRA OS Recovery Act 2009 Limited Competition Comparative Effectiveness Delivery System Evaluation Grants (R01) Apply for RFA HS 10 012 Funding Number: RFA HS 10 012 Agency: Agency for Health Care Research and Quality Category: Health Recovery Act Funding Amount: $500,000 |
| ARRA OS Recovery Act 2009 Limited Competition Comparative Effectiveness Delivery System Demonstration Grants (R18) Apply for RFA HS 10 013 Funding Number: RFA HS 10 013 Agency: Agency for Health Care Research and Quality Category: Health Recovery Act Funding Amount: Case Dependent |
| ARRA OS Recovery Act 2009 Limited Competition Enhanced State Data for Analysis and Tracking of Comparative Effectiveness Impact Improved Clinical Content and Race Ethnicity Data (R01) Apply for RFA HS 10 010 Funding Number: RFA HS 10 010 Agency: Agency for Health Care Research and Quality Category: Health Recovery Act Funding Amount: Case Dependent |
| Recovery Act Limited Competition The NIH Directors ARRA Funded Pathfinder Award to Promote Diversity in the Scientific Workforce (DP4) Apply for RFA OD 10 013 Funding Number: RFA OD 10 013 Agency: National Institutes of Health Category: Health Recovery Act Funding Amount: $2,000,000 |
| 2010 ARRA Prevention and Wellness Leveraging National Organizations Apply for OS PAW 10 001 Funding Number: OS PAW 10 001 Agency: Office of the Assistant Secretary for Health Category: Health Recovery Act Funding Amount: $1,500,000 |
| ARRA Training in Primary Care Medicine Interdisciplinary and Interprofessional Joint Graduate Degree Apply for HRSA 10 236 Funding Number: HRSA 10 236 Agency: Health Resources and Services Administration Category: Health Recovery Act Funding Amount: Case Dependent |
| ARRA Training in Primary Care Medicine Physician Assistant Training in Primary Care Apply for HRSA 10 234 Funding Number: HRSA 10 234 Agency: Health Resources and Services Administration Category: Health Recovery Act Funding Amount: Case Dependent |
| ARRA Training in Primary Care Medicine Predoctoral Training in Primary Care Apply for HRSA 10 233 Funding Number: HRSA 10 233 Agency: Health Resources and Services Administration Category: Health Recovery Act Funding Amount: Case Dependent |
| ARRA Training in Primary Care Medicine Physician Faculty Development in Primary Ca Apply for HRSA 10 232 Funding Number: HRSA 10 232 Agency: Health Resources and Services Administration Category: Health Recovery Act Funding Amount: Case Dependent |
| ARRA Training in Primary Care Medicine Administrative Academic Units in Primary Care Apply for HRSA 10 231 Funding Number: HRSA 10 231 Agency: Health Resources and Services Administration Category: Health Recovery Act Funding Amount: Case Dependent |
| American Recovery and Reinvestment Act of 2009, Funding to Beacon Communities Apply for HHS 2010 ONC BC 006 Funding Number: HHS 2010 ONC BC 006 Agency: Office of the National Coordinator Category: Health Recovery Act Funding Amount: $18,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA OD 10 010", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.